SCHEMBL23535544

SCHEMBL23535544

COC(=O)c1ccc(Nc2cc(Cl)ncc2N)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK1 Q13464 1/20 0.49
SIRT2 Q8IXJ6 1/20 0.48
KDM4E B2RXH2 4/20 0.47
KMT2A Q03164 4/20 0.47
HPGD P15428 2/20 0.47
MEN1 O00255 2/20 0.47
RXFP1 Q9HBX9 1/20 0.47
MAPT P10636 5/20 0.44
MITF O75030 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
CDC25A P30304 1/20 0.43
CDC25B P30305 1/20 0.43
MAPK1 P28482 4/20 0.43
POLB P06746 1/20 0.43
GAA P10253 3/20 0.42
ALDH1A1 P00352 1/20 0.42
GLA P06280 1/20 0.42
CASP1 P29466 1/20 0.42
CASP7 P55210 1/20 0.42
ATM Q13315 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29492772 0.81 MAPT (0.52) KDM4EKMT2AMEN1MAPTTDP1
SCHEMBL24270569 0.81 MAPT (0.52) KDM4EKMT2AMEN1MAPTTDP1
SCHEMBL23535498 0.80 MAPT (0.58) KMT2AMEN1MAPTTDP1MAPK1
SCHEMBL27252190 0.80 GAA (0.47) KDM4EKMT2AHPGDMEN1MAPT
SCHEMBL27473173 0.79 PIK3CA (0.53) KMT2AMEN1USP2SMN1; SMN2
SCHEMBL30962579 0.78 PIK3CA (0.52) KMT2AMEN1USP2SMN1; SMN2
SCHEMBL17047603 0.76 KDM4E (0.36) KDM4EKMT2AHPGDMEN1MAPT
SCHEMBL24270834 0.75 GAA (0.50) KDM4EKMT2AHPGDMEN1MAPT
SCHEMBL29492714 0.75 GAA (0.50) KDM4EKMT2AHPGDMEN1MAPT
SCHEMBL4874060 0.74 NPC1 (0.57) ROCK1KDM4EKMT2AHPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115768757-A CD206 modulators and uses and methods of making thereof 美利坚合众国,由健康及人类服务部部长代表 2023-03-07 CN disclosed
US-20230056497-A1 CD206 Modulators Their Use and Methods for Preparation US HEALTH (US) 2023-02-23 US disclosed
EP-4077297-A1 CD206 MODULATORS THEIR USE AND METHODS FOR PREPARATION The United States Of America, As Represented By The Secretary, Department Of Health And Human Services (US) 2022-10-26 EP disclosed
WO-2021126923-A1 CD206 MODULATORS THEIR USE AND METHODS FOR PREPARATION THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) 2021-06-24 WO disclosed
WO-2021126923-A1 CD206 MODULATORS THEIR USE AND METHODS FOR PREPARATION THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) 2021-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230056497-A1 CD206 Modulators Their Use and Methods for Preparation CD209, MSR1, ARG1 ROCK1 1312/4885SIRT2 2096/4885KDM4E 3295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.